In the BioHarmony Drug Report Database
Trogarzo (ibalizumab) is an antibody pharmaceutical. Ibalizumab was first approved as Trogarzo on 2018-03-06. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. The pharmaceutical is active against T-cell surface glycoprotein CD4.
Image (chem structure or protein)